FloraSeq was founded in Waukesha, WI in 2014 to leverage the knowledge of the human microbiome for the treatment of gastrointestinal disorders and to maintain gut health. The founders are Steve Visuri and Karen Harrington who have over 40 years of experience in medical devices and diagnostics with senior leadership positions at Prodesse, Gen-Probe, and Hologic. FloraSeq is initially focused on developing a highly unique live biotherapeutic agent (similar to probiotics) for the treatment of clostridium difficile (C. diff) infections. This bacterium causes debilitating and deadly gastrointestinal infections in over a million patients per year and is one of the most prevalent and concerning hospital-acquired infections. Beyond the billion dollar C. diff therapeutic market, the approach is relevant to a wide array of GI applications including Inflammatory Bowel Disease and Irritable Bowel Syndrome.